drugset / Trial / NCT04802980
A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of HB002.1T in combination with different chemotherapy regimens administered to patients with advanced solid tumors.
Timeline
- Start
- 2020-04-28
- Primary completion
- 2023-07-15
- Completion
- 2023-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB002.1T | Protein / enzyme biologic | — | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |